AroCell AB (publ) (AROC.ST)
SEK 0.38
(-4.98%)
SEK 0.38
(-4.98%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 43.03 Million SEK | 16.37% |
| 2022 | 36.98 Million SEK | 208.32% |
| 2021 | 11.99 Million SEK | 14180.95% |
| 2020 | 84 Thousand SEK | -81.03% |
| 2019 | 442.69 Thousand SEK | -43.38% |
| 2018 | 781.84 Thousand SEK | 55.73% |
| 2017 | 502.03 Thousand SEK | 819.37% |
| 2016 | 54.6 Thousand SEK | -88.13% |
| 2015 | 460.21 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 26.85 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 12.8 Million SEK | 34.61% |
| 2024 Q3 | 13.99 Million SEK | -8.36% |
| 2024 Q2 | 15.27 Million SEK | 19.29% |
| 2023 FY | 43.03 Million SEK | 16.37% |
| 2023 Q3 | 10.7 Million SEK | -9.13% |
| 2023 Q2 | 11.77 Million SEK | 6.53% |
| 2023 Q4 | 9.51 Million SEK | -11.11% |
| 2023 Q1 | 11.05 Million SEK | -11.34% |
| 2022 Q1 | 7.77 Million SEK | 31.83% |
| 2022 Q4 | 12.46 Million SEK | 19.86% |
| 2022 Q3 | 10.4 Million SEK | 63.82% |
| 2022 Q2 | 6.34 Million SEK | -18.29% |
| 2022 FY | 36.98 Million SEK | 208.32% |
| 2021 Q1 | 43 Thousand SEK | 115.0% |
| 2021 Q3 | 6.02 Million SEK | 19996.67% |
| 2021 Q4 | 5.89 Million SEK | -2.24% |
| 2021 FY | 11.99 Million SEK | 14180.95% |
| 2021 Q2 | 30 Thousand SEK | -30.23% |
| 2020 Q1 | 64 Thousand SEK | -46.53% |
| 2020 Q4 | 20 Thousand SEK | 0.0% |
| 2020 FY | 84 Thousand SEK | -81.03% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | -100.0% |
| 2019 Q4 | 119.69 Thousand SEK | -0.25% |
| 2019 Q3 | 120 Thousand SEK | -5.51% |
| 2019 FY | 442.69 Thousand SEK | -43.38% |
| 2019 Q1 | 76 Thousand SEK | 47898.74% |
| 2019 Q2 | 127 Thousand SEK | 67.11% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q2 | 621 Thousand SEK | 0.0% |
| 2018 FY | 781.84 Thousand SEK | 55.73% |
| 2018 Q4 | -159.00 SEK | -100.1% |
| 2018 Q3 | 162 Thousand SEK | -73.91% |
| 2017 Q4 | 209.03 Thousand SEK | 0.0% |
| 2017 FY | 502.03 Thousand SEK | 819.37% |
| 2017 Q3 | - SEK | -100.0% |
| 2017 Q2 | 237 Thousand SEK | 323.21% |
| 2017 Q1 | 56 Thousand SEK | 221.74% |
| 2016 FY | 54.6 Thousand SEK | -88.13% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | 46 Thousand SEK | 0.0% |
| 2016 Q4 | -46 Thousand SEK | -200.0% |
| 2015 FY | 460.21 Thousand SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | 460.21 Thousand SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q1 | - SEK | -100.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q4 | 2000.00 SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q4 | 13.85 Thousand SEK | 0.0% |
| 2010 FY | 26.85 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | 169.3 Million SEK | 74.578% |
| Immunovia AB (publ) | 1.57 Million SEK | -2632.635% |
| Prostatype Genomics AB (publ) | 1.35 Million SEK | -3073.968% |
| SenzaGen AB | 49.87 Million SEK | 13.698% |
| Spermosens AB | - SEK | -Infinity% |